IWD2024: Pushing for newsroom policies and culture of equal opportunities for women

Globally, research shows that more women, than men, enrol into journalism schools and move on to pursue careers in the journalism vocation. However, it is their male counterparts who dominate senior editorial and managerial positions in many media organisations. This state of gender disparity within newsrooms, is partly what accounts for the dominant masculine news values that tilt media content in favour of men’s issues to the relegation of women’s issues.

The factors that continue to drive this gender disparity remain largely similar but tend to be nuanced under the influence of socio-cultural factors that differ from one region of the world to another. In West Africa, the drivers remain deeply ingrained cultural stereotypes that position women as better suited for more docile roles in newsrooms.

For instance, as research shows, there is a widespread perception that women are better suited for glamorous news anchoring roles, rather than investigative journalism duties. And in television, women tend to have their value measured more in terms of their physical looks and appearance than skill and qualification, the research reported.

But these stereotypes are really, just what they are – stereotypes; because in spite of all of these barriers, women journalists keep proving themselves very capable of the demands of journalism, irrespective of variety or style. And for the few female journalists who have broken through the glass ceiling to occupy editorial and managerial roles of media organisations, their stories and triumphs remain compelling examples; this is whether it is Ifeyinwa Omowole, Editor-in-chief of the Nigeria News Agency, Khadija Patel, chairperson of the International Press Institute and former editor-in-chief of the Mail & Guardian, or Jamila Akweley Okertchiri, first female editor of the Daily Guide newspaper in Ghana.

On the occasion of the International Women’s Day, the theme – ‘Invest in Women: Accelerate Progress,’ is a fitting call to action. For stakeholders in media, it provides stimulus to advance activism that confronts the existing gendered stereotypes that antagonise women in newsrooms.  This call to action invites stakeholders to once more galvanize and make another push for the cause to achieve newsrooms that offer equal career opportunities to women, just as it offers to men.

This is not to imply that there has been lack of activism and progress in the fight for gender equity in newsrooms in West Africa; many stakeholders have long been at work confronting gender disparity by means of various strategies. At the Media Foundation for West Africa (MFWA), for instance, the strategies have included various forms of journalism training programmes in which a standard requirement is that at least 40% of the beneficiaries are female. An example of an empowerment programme in which this requirement is applied is the MFWA’s Next Generation Investigative Journalism (NGIJ) Fellowship.

In addition, the MFWA also undertakes regular training programmes on issues such as fact-checking, data journalism and mobile journalism for beneficiaries, 40% of whom must be women.

But even with interventions such as those by the MFWA, room still remains for a lot more to be done. West African governments have been particularly notorious for being slow adopters of gender equity policies and even where they do adopt such, implementation is often shambolic. As research has long confirmed that women catalyse development, these lackadaisical attitudes by governments must change in all regards, including, in the adoption and implementation of policies that create equity for women in all contours of the macro and micro economic value chain.

Governments should not only implement gender equity policies but should be seen to be doing so as such actions on the part of governments are powerful for conscientizing citizens on the need for gender equity.

Civil society is definitely to be commended for the years of investment in, and activism for gender parity in West Africa, but the theme for this year’s commemoration of International Women’s Day is a further call on CSOs to not fall back but to renew commitment to the cause of gender equity.

For media organisations, this commemoration should galvanize resolve to intentionally make newsrooms more equitable, while for women journalists themselves, the challenge is to assert their value as journalists who are as capable as their male counterparts.

Meanwhile, the call to action should also be seen as a challenge to ECOWAS to do more for the enhancement of women’s rights. In this regard, a more aggressive fostering of the ECOWAS Treaty for gender equality, under Article 63, is imperative.

Hitachi Energy to appoint Andreas Schierenbeck as new Chief Executive Officer, Claudio Facchin to step down on June 30, 2024

Zurich, March 07, 2024 (GLOBE NEWSWIRE) — Hitachi Energy today announced that Andreas Schierenbeck will be appointed as the new Chief Executive Officer, effective July 1, 2024. Claudio Facchin, Hitachi Energy CEO, will step down at the end of June 2024. Andreas will engage with the Hitachi Energy Board, Executive Team and Claudio to ensure a smooth transition prior to the handover on July 1, 2024.

Andreas joins Hitachi Energy from HH2E, a new green-hydrogen production company, where he is currently co-founder and board member. He previously worked as CEO of Uniper from 2019 to 2021, where he launched the company’s decarbonization strategy. Prior to that he was the CEO of thyssenkrupp Elevator, where he led the transformation of the company into a global leader leveraging digital technology from 2013 to 2018. Between 1992 and 2012, Andreas held various management positions within Siemens, including President and CEO of Siemens Building Technologies in the US between 2010 and 2012 and Senior Vice President in the Siemens electric utility sector in Switzerland. He holds a Master of Science degree in Electrical Engineering from the TU Dresden and an Advanced Management Certificate from Harvard University in the US. Andreas is a German citizen.

“I would like to welcome Andreas to Hitachi Energy to lead the next phase of exciting growth for the business. I would also like to express my appreciation to Claudio for his great leadership transitioning and transforming the company over the last four years from the carve-out of ABB’s Power Grids business through the Hitachi ABB Power Grids Joint Venture (JV) into Hitachi Energy, a fully-owned subsidiary of Hitachi Group”, said Keiji Kojima, Representative Executive Officer, President & CEO of Hitachi, Ltd. “I look forward to continuing to support Hitachi Energy’s growth plan under the leadership of Andreas, and I wish Claudio all the best for the journey ahead.”

“Following a planned transition and a thorough selection process, we have appointed Andreas Schierenbeck as the successor to Claudio Facchin”, said Alistair Dormer, Chair of Hitachi Energy and Executive Vice President, Executive Officer and General Manager of Green Energy & Mobility Strategy Planning Division, Hitachi Ltd. “Claudio can be proud of his four years as CEO, and it has been a pleasure working with him during the past two years, supporting him and the Executive Team to deliver the transformation into Hitachi Energy, the leading power grids technology and solution provider. The Hitachi Energy 2030 growth plan centered around the commitment to continuously invest in innovation and partnerships to serve our customers is a solid foundation to build on, and I look forward to working with Andreas and the entire Hitachi Energy leadership team as we accelerate the delivery of the Hitachi Energy growth plan. Andreas’ experience of delivering transformational growth across sectors will help Hitachi Energy to scale growth and synergies with Hitachi.”

“It’s been an honor and a privilege to lead the transition to Hitachi Energy, working alongside the Executive Team and the entire Hitachi Energy organization across the globe”, said Claudio Facchin, CEO of Hitachi Energy. “The authentic passion and unwavering ownership of this team has been a limitless source of energy and motivation for me personally. Together with Hitachi teams, we have worked with customers and partners to advance the world’s energy system to be more sustainable, flexible and secure. The extraordinary achievements of Hitachi Energy would not have been possible without the continuous support from Hitachi Group. I look forward to onboarding Andreas, together with the Executive Team and the Board of Hitachi Energy, until the handover on July 1, 2024.”

“I am thrilled to embark on this journey as the new CEO of Hitachi Energy, steering the company towards new horizons in an era of transformation, where the demand for electricity is surging due to the rapid electrification of transport, buildings, and industries”, said Andreas Schierenbeck. “It is a profound honor to lead an experienced team so deeply committed to quality, innovation and sustainability as we help our customers and society accelerate towards a greener future. Together, we will continue to expand Hitachi Energy’s profitable business, ensuring that our collective efforts contribute significantly to a sustainable and electrified future.”

Hitachi Energy to appoint Andreas Schierenbeck as new Chief Executive Officer

About Hitachi Energy
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. We integrate more than 150 GW of HVDC links into the power system, helping our customers enable more wind and solar. Headquartered in Switzerland, we employ more than 40,000 people in 90 countries and generate business volumes of over $10 billion USD.


About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.


Global Media Relations
Hitachi Energy

GlobeNewswire Distribution ID 9059761

Dentsu Appoints Shirli Zelcer to Chief Data and Technology Officer

Steve Simpson joins as President, Data, Audiences and Technology; Shiva Vannavada appointed as President, Data and Technology Solutions

Shirli Zelcer

Chief Data & Technology Officer, dentsu

TOKYO, March 07, 2024 (GLOBE NEWSWIRE) — Dentsu (brand: dentsu; Head Office: Dentsu Group Inc.; Location: Tokyo; Representative: President and Global CEO Hiroshi Igarashi) today announced the appointment of Shirli Zelcer as Chief Data and Technology Officer (CDTO), sitting on dentsu’s Group Management Team. In this role, Zelcer will be responsible for all of dentsu’s client-facing data-driven, analytics and technology-enabled products and platforms, driving innovation and sustainable growth for clients.

Dentsu also announced today that Steve Simpson has been appointed as President, Data, Audiences and Technology, dentsu and Shiva Vannavada as President, Data and Technology Solutions, dentsu. Simpson will join the Global Media Practice leadership team to support the development of a winning Media Practice community that delivers continued excellence in its offering to clients, driving client growth and transformation. In his newly created role, Simpson will be responsible for the strategic planning and delivery of a globally-scaled, data-driven and technology-enabled audience platform that drives growth for clients, while Vannavada will focus on creating synergies across product and platforms, AI innovation, analytics and across Dentsu Global Services (DGS).

Zelcer brings over 20 years of experience in analytics and insights, business advisory and organizational design, AI and data science, and cloud and marketing technologies. She was most recently the Global Head of Analytics and Technology at Merkle, where she led a global division of over 5,600 practitioners across the Americas, EMEA, and APAC. In her new role at dentsu, Zelcer will be responsible to innovate the vision, roadmap, development and commercial impact of dentsu’s data and tech strategy across our three core practice areas: Media, CXM and Creative, working closer with Practice leads and Jean Lin, Global President – Global Practices, dentsu. The role will lead a newly formed team brought together from these Practice areas to drive consistency, interoperability and ultimately to deliver growth to dentsu’s clients through more unified capabilities.

Joining from Publicis, in his new role, Simpson will lead a global team of experts from across data management, identity, personalization, media activation and dynamic creative production, and partner with dentsu’s global products and platforms team to integrate and scale the platform across dentsu’s Global Practices.

Simpson will also be accountable for evolving dentsu’s global media delivery platform. Enabled by programmatic media delivery, enriched with 1st, 2nd and 3rd party data, it will leverage dentsu’s leading Merkury products suite to drive client competitiveness.

Having previously served as Global Chief Product and Technology Officer, dentsu Solutions, Vannavada’s expanded responsibilities as President, Data and Technology Solutions will include driving cross-practice and product collaboration, nurturing dentsu’s AI Connective community and leading his team to contribute to tech-enabled solutions and strategy.

“Innovation across data and technology are two of dentsu’s most critical points of differentiation, having led the market for many years in the development, adoption and application of proprietary platforms which give our clients the edge,” said Hiroshi Igarashi, President and Global CEO, dentsu. “We are very proud to appoint Shirli, Steve and Shiva into these new strategic roles which bring together our efforts across the organization, honing our capabilities and ensuring that dentsu and our clients remain at the forefront of innovation.”

The leadership of the broader Data and Tech organization at dentsu includes: Head of Product, Matt Seeley, and Sunil Rao leading Analytics, and Peter Rogers leading Data Platforms. DGS will also now report into Zelcer’s Data and Technology structure and in turn, Zelcer will report into Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu.


“During her time at Merkle, Shirli brought together teams from around the world to collaborate on vital programs, ranging from data infrastructure implementation to advanced media mix modeling, personalization strategies and the development of bespoke AI solutions,” commented Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu. “With her vast experience of successfully partnering with clients, alongside a proven ability to solve business challenges with cutting-edge technology solutions, I’m truly excited to see the impact that Shirli will have in her new expanded global role at dentsu.”

“It is a very exciting prospect to move into this new role at a time when not only is dentsu at a pivotal moment in its history, but data and technology have never evolved at a faster pace,” remarked Shirli Zelcer, Chief Data and Technology Officer, dentsu. “As a group, we have already made some big moves into AI over the last few years, but I truly see the combination of AI with dentsu proprietary and partner technologies as a major differentiator for our clients. I’m looking forward to broadening the impact I can have across dentsu and working closely with the talented leaders and teams across our tech community.”

Steve Simpson, President, Data, Audiences and Technology, dentsu, said: “I am thrilled to join dentsu at this exciting time of transformation and innovation. Data and technology are at the heart of the media industry and the integrated opportunity across Practices at dentsu in vast. I look forward to working with the talented teams throughout dentsu to build a world-class platform that will deliver value and innovation for our clients, helping them achieve their business goals.”

Shiva Vannavada, President, Data and Technology Solutions, dentsu, commented: “Since I began my journey at dentsu, we have been actively planning our future with AI and I am excited to take on this new expanded remit as we enter into what will undoubtedly be a transformational year for AI and the products and solutions we build using it. At dentsu, we don’t consider AI as a standalone technology, it is part of the fabric of our data, technology and product capabilities, ingrained into every practice and present in every agency brand. This makes us naturally more collaborative, more integrated and faster to market for our clients, and I look forward to working with teams across dentsu to break new ground in what is possible across data and tech for our clients.”

About dentsu

Dentsu is the network designed for what’s next, helping clients predict and plan for disruptive future opportunities and create new paths to growth in the sustainable economy. Taking a people-centered approach to business transformation, we use insights to connect brand, content, commerce and experience, underpinned by modern creativity. As part of Dentsu Group Inc. (Tokyo: 4324; ISIN: JP3551520004), we are headquartered in Tokyo, Japan, and our 71,000-strong employee base of dedicated professionals work across four regions (Japan, Americas, EMEA and APAC). Dentsu combines Japanese innovation with a diverse, global perspective to drive client growth and to shape society.



Matt Cross
Phone: +442074306319
Email: matt.cross@dentsu.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf533a57-ac1f-4ad2-87e5-340b90ec6957

GlobeNewswire Distribution ID 1000927842

Zenas BioPharma Nomeia Patricia Allen para o Conselho Diretor

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia, divulgou hoje a nomeação de Patricia Allen para o Conselho Diretor, onde atuará também como Presidente do Comitê de Auditoria. A Sra. Allen ingressa no Conselho Diretor da Zenas com mais de 20 anos de experiência liderando finanças, relações com investidores, desenvolvimento de negócios, recursos humanos, operações e TI em empresas globais públicas e privadas de biotecnologia.

“Estamos muito contentes com a vinda de Patty para o nosso Conselho Diretor”, disse Lonnie Moulder, Fundador e Diretor Executivo da Zenas BioPharma. “Ela liderou com sucesso funções interorganizacionais e atuou no conselho diretor de empresas privadas e públicas de biotecnologia global. Estamos prontos para as contribuições de Patty para a próxima fase do crescimento da Zenas, à medida que avançamos na nossa missão de desenvolver e comercializar terapias transformadoras baseadas em imunologia para pacientes necessitados.”

“Estou pronta para colaborar com a experiente equipe da Zenas e o Conselho Diretor, que estão ampliando uma empresa biofarmacêutica global líder em inflamação e imunologia por meio da execução disciplinada de pipeline e desenvolvimento de negócios”, disse a Sra. Allen. “A Zenas está muito empolgada com o progresso dos seus múltiplos programas clínicos que irão aprimorar as vidas das pessoas que sofrem de doenças autoimunes.”

Recentemente, a Sra. Allen atuou como Diretora Financeira da Vividion Therapeutics, de onde se aposentou recentemente. Na Vividion, ela co liderou a captação de recursos e a aquisição da empresa pela Bayer AG, durante o crescimento e avanço da empresa com vários programas em direção à clínica. Ela atua no conselho diretor e como presidente do comitê de auditoria da Deciphera Pharmaceuticals, SwanBio Therapeutics e Anokion, além de ser ex-membro do conselho e presidente do comitê de auditoria da Inversago Pharma e Yumanity Therapeutics.

Antes de ingressar na Zenas, a Sra. Allen atuou como Diretora Financeira da Zafgen, Inc. (atual Larimer Therapeutics). Anteriormente, ela foi Vice-Presidente de Finanças e Tesoureira, Diretora Financeira Principal da Alnylam Pharmaceuticals, Inc.; Diretora de Finanças da Alkermes, Inc.; e Auditora da Deloitte & Touche, LLP. Ela é formada em Administração de Empresas pelo Bryant College.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia para pacientes necessitados em todo o mundo. Com desenvolvimento clínico e operações globais, a Zenas está avançando um portfólio de terapêuticas autoimunes potencialmente diferenciadas em áreas de alta necessidade médica. Aproveitamos a experiência e a capacidade da nossa equipe de gestão executiva a das nossas existentes na indústria biofarmacêutica em busca do desenvolvimento de terapias que possam melhorar as vidas das pessoas com doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no (ex Twitter ) em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Argot Partners

GlobeNewswire Distribution ID 9059519

Patricia Allen rejoint le Conseil d’administration de Zenas BioPharma

WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la commercialisation de thérapies orientées sur l’inflammation et l’immunologie, annonce la nomination de Patricia Allen à son Conseil d’administration et à la Présidence de son comité d’audit. Mme Allen rejoint le Conseil d’administration de Zenas après avoir dirigé pendant plus de 20 ans différentes divisions pour le compte de sociétés biotechnologiques internationales publiques et privées, notamment les départements des finances, relations avec les investisseurs, développement commercial, ressources humaines, opérations et informatique.

À propos de cette nomination, Lonnie Moulder, fondateur et PDG de Zenas BioPharma a déclaré : « Nous sommes ravis d’accueillir Patty au sein de notre Conseil d’administration. Elle a piloté avec succès des divisions transverses pour différentes entreprises, et a siégé au Conseil d’administration de sociétés biotechnologiques d’envergure mondiale des secteurs public et privé. Nous attendons avec impatience sa participation à la prochaine phase de croissance de Zenas, à l’heure où notre mission visant à développer et distribuer des immunothérapies modératrices du changement pour les patients qui en ont besoin prend de l’ampleur. ».

« J’ai hâte de travailler avec le concours des équipes expérimentées de Zenas et son Conseil d’administration, qui bâtissent ensemble une société biopharmaceutique internationale de premier plan axée sur des stratégies thérapeutiques orientées sur l’inflammation et l’immunologie au prix d’une exécution rigoureuse de leur pipeline et du développement commercial » observe Mme Allen, avant de poursuivre : « Le laboratoire Zenas traverse une période exaltante à l’heure où il s’efforce d’atteindre la phase clinique pour plusieurs de ses programmes dans l’objectif d’améliorer la vie des patients atteints de maladies auto-immunes ».

Actuellement retraitée, Mme Allen occupait encore très récemment la Direction des affaires financières de Vividion Therapeutics, dont elle a codirigé la levée de fonds et l’acquisition de Bayer AG, au moment où la société était en pleine croissance et faisait progresser plusieurs de ses programmes vers la phase clinique. Elle figure actuellement parmi les membres du Conseil d’administration de Deciphera Pharmaceuticals, SwanBio Therapeutics et Anokion, dont elle préside les comités d’audit, après avoir siégé aux Conseils d’administration des sociétés Inversago Pharma et Yumanity Therapeutics et en avoir également présidé les comités d’audit.

Avant son passage chez Vividion, Mme Allen pilotait la Direction financière de Zafgen, Inc., aujourd’hui Larimer Therapeutics. Avant cela, elle était vice-présidente des affaires financières, ainsi que trésorière et responsable financière principale chez Alnylam Pharmaceuticals, Inc., directrice des finances chez Alkermes, Inc., et auditrice chez Deloitte & Touche, LLP. Elle est titulaire d’une licence en gestion d’entreprises sanctionné par l’université privée américaine Bryant.

À propos de Zenas BioPharma

Zenas BioPharma est un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la commercialisation de thérapies orientées sur l’inflammation et l’immunologie pour répondre aux besoins des patients concernés partout dans le monde. À l’appui de ses capacités de développement et de ses installations de recherche clinique implantées aux quatre coins de la planète, Zenas fait progresser un ensemble de thérapies potentiellement différenciatrices ciblées sur les maladies auto-immunes dans des domaines thérapeutiques où les besoins médicaux restent insatisfaits. Son équipe de direction chevronnée et son réseau de partenaires commerciaux stimulent l’excellence opérationnelle visant à concevoir des traitements potentiellement révolutionnaires aux fins d’améliorer la qualité de vie des patients atteints de maladies auto-immunes rares. Pour en savoir plus sur Zenas BioPharma, rendez-vous sur www.zenasbio.com et suivez-nous sur X (anciennement Twitter) @ZenasBioPharma et LinkedIn.

Relations auprès des investisseurs et des médias :
Agence Argot Partners

GlobeNewswire Distribution ID 9059519